Playnance to launch G Coin ahead of token event
Playnance said it will launch G Coin on March 18, introducing a utility token designed to power transactions across its blockchain-based gaming and prediction market ecosystem.

TV presenter and finance editor at Grafa, with a Master’s in Commerce from UWA and diverse industry experience in finance, insurance, and media.
Playnance said it will launch G Coin on March 18, introducing a utility token designed to power transactions across its blockchain-based gaming and prediction market ecosystem.
MicroStrategy founder Michael Saylor suggested the company’s continued Bitcoin buying may precede future supply squeezes, arguing markets often react only after sustained accumulation tightens available supply.
Collins Foods has entered a binding Heads of Agreement to settle a class action regarding 10-minute rest breaks for up to $9 million.
The legal proceedings, which commenced in December 2023, involved claims from employees against the company and several other respondents regarding workplace entitlements.
Gyre Therapeutics (NASDAQ:GYRE) reported a year of strategic transformation and steady financial growth for the full year 2025, posting total revenue of $116.6 million, a 10.2% increase compared to the prior year.
Titomic (ASX:TTT) plans a strategic redomicile to the US by late 2026 to integrate into the global defence and aerospace sector.
Javelin Minerals (ASX:JAV) announced a binding agreement to acquire the Central Yilgarn Gold Project.
The International Energy Agency announced that its 32 member nations have unanimously agreed to release 400 million barrels of oil from emergency reserves.
ProQR Therapeutics (NASDAQ:PRQR), a Leiden, Netherlands-based clinical-stage biotechnology company developing RNA-based therapies for severe genetic rare diseases, on Thursday reported a net loss of $9.1 million for its fourth quarter ended December 31, 2025.
Seres Therapeutics (NASDAQ:MCRB) delivered a rare profitable year in 2025, though the black ink was the result of a major divestiture rather than a surge in drug sales.
United Homes Group (NASDAQ:UHG) saw its bottom line bolstered by non-cash accounting gains in the final quarter of 2025, even as the homebuilder navigated a cooling market for new orders and production.